NSTL国家科技图书文献中心

1. Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial NSTL国家科技图书文献中心

Sureda, Anna | Pinto, Antonio ... - 《Hematological oncology》 - 2025,43(1) - e70000～e70000 - 共11页

摘要： efficacy of the RP2D in expansion* cohorts of selected R/R* | A significant unmet need remains for patients | with Hodgkin lymphoma (HL) who fail to respond to | first-line treatment or experience an early relapse | . Tinostamustine, a novel alkylating deacetylase inhibitor

关键词： alkylating agents | hematological malignancy/ies | histone deacetylase inhibitors | Hodgkin(s) lymphoma | phase I trial | tinostamustine

2. Changes in upper airway airflow after rapid maxillary expansion considering normal craniofacial development as a factor: a retrospective study using computer fluid dynamics NSTL国家科技图书文献中心

Antonino,Lo Giudice | Alessandro,Polizzi ... - 《European journal of orthodontics》 - 2025,47(1) - cjae077～cjae077 - 共12页

摘要： maxillary expansion* (RME). However, the medium-term* | underwent RME divided into two cohorts: a 6−9-year-old | group (EEG group: early expansion* group − 25 subjects* | expansion group − 23 subjects). The nasal cavity and | maxillary expansion* (PW) amount, two cross-sectional area*

关键词： maxillary expansion | upper airways | digital orthodontics | RME | 3D Imaging | CBCT

3. A Revised Optical Coherence Tomography-Derived Calcium Score to Predict Stent Underexpansion in Severely Calcified Lesions NSTL国家科技图书文献中心

Sato, Takao | Matsumura, Mitsuaki ... - 《JACC.Cardiovascular interventions》 - 2025,18(5) - 622～633 - 共12页 - 被引量：2

摘要： derivation (n =167) and validation (n = 83) cohorts. The | endpoint was stent expansion* (minimum stent area/average* | deposition site, and stent expansion* <70% was considered* | characteristics associated with stent expansion* in the* | correlated with stent expansion* (regression coefficient*

关键词： optical coherence tomography | percutaneous coronary intervention | severe calcified plaque | stent(s)

4. Genetic and Clinical Features of 10 Families With Hereditary Sensory Neuropathies NSTL国家科技图书文献中心

Ke Xu | Zhongzheng Li ... - 《Journal of the peripheral nervous system》 - 2025,30(2) - e70020～e70020 - 共11页

摘要：. Additionally, biallelic expansion* of the pathogenic variant* | HSNs, future multicenter studies with larger cohorts | Background and objectives: Hereditary sensory | neuropathies (HSNs) are a group of genetically and clinically | heterogeneous diseases. Our study aims to summarize the

关键词： NTRK1; PUM1; ataxia; genetic and clinical features; hereditary sensory neuropathies.

5. Demystifying the Etiology of ILOCA in the Genomic Era: A Narrative Review NSTL国家科技图书文献中心

Luiz Eduardo,Novis | Thiago Yoshinaga Ton...... - 《The cerebellum》 - 2025,24(2) - Article 45～Article 45 - 共10页

摘要： expansion disorders such as Spinocerebellar Ataxia type 27 | mutations are also frequently observed in large cohorts | Abstract Background Idiopathic Late-Onset | Cerebellar Ataxia (ILOCA) is a challenging and | heterogeneous disorder characterized by progressive cerebellar

关键词： Idiopathic late-onset Cerebellar ataxia | Sporadic Adult Onset Cerebellar ataxia | Next Generation Sequencing

6. Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti‐tumour T‐cell activation – IRE‐IMMUNO study NSTL国家科技图书文献中心

Bart Geboers | Matthijs J. Scheltem...... - 《BJU international》 - 2025,135(2) - 319～328 - 共10页 - 被引量：1

摘要： between treatment cohorts. Results Patient and tumour | characteristics were similar between the cohorts* except for age* | . Accordingly, IRE induced expansion* of PSAP and/or NY‐ESO‐1* | Objectives To prospectively compare systemic | anti‐tumour immune responses induced by irreversible

关键词： prostate cancer | irreversible electroporation | abscopal effect | immune response | immunotherapy | ablation | focal therapy

7. The Mobile lifestyle intervention for food and exercise (mLife) study: Protocol of a remote behavioral weight loss randomized clinical trial for type 2 diabetes prevention NSTL国家科技图书文献中心

Dubois, K. E. | Delgado-Diaz, D. C.... - 《Contemporary clinical trials》 - 2025,148 - 107735～107735 - 共9页

摘要： = 240) in two consecutive cohorts* were randomized to* | expansion of gamification within mHealth programs to | Background: Emerging research has examined | electronic and mobile health (e/mHealth) technologies for | weight loss and manage of type 2 diabetes mellitus

关键词： Randomized controlled trial | Weight loss | Mobile health | Social support | Obesity | Diet tracking | Physical activity tracking | Gamification

8. A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation NSTL国家科技图书文献中心

Aubrey, Brandon J. | Blonquist, Traci ... - 《Leukemia Research》 - 2025,153 - 107693～107693 - 共8页

摘要： additional 9 expansion* patients were treated at this dose* | expansion, grade 4 toxicities attributed to study drug | cohorts (n = 21), 1 patient (4.8 %) achieved CR and 3 | Background: Allogeneic hematopoietic cell | transplantation (HCT) may improve long-term survival in patients

关键词： AML | MDS | Bortezomib | Lenalidomide | Allogeneic stem cell transplant

9. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors NSTL国家科技图书文献中心

Apolo, Andrea B. | Girardi, Daniel M.... - 《Journal of clinical oncology》 - 2024,42(25) - 3033～3046 - 共14页

摘要： I trial. CaboNivo doublet expansion cohorts | bladder/urachal; CaboNivoIpi triplet expansion cohorts | ) of the phase I patients and seven expansion | PURPOSECabozantinib and nivolumab (CaboNivo | ) alone or with ipilimumab (CaboNivoIpi) have shown

关键词： METASTATIC UROTHELIAL CARCINOMA | PLUS CABOZANTINIB | COMBINATION | CELLS

10. The 3+3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies NSTL国家科技图书文献中心

Chiuzan, Cody | Dehbi, Hakim-Moulay - 《Clinical trials: journal of the Society for Clinical Trials》 - 2024,21(3) - 350～357 - 共8页 - 被引量：1

摘要：In the last few years, numerous novel designs | have been proposed to improve the efficiency and | accuracy of phase I trials to identify the maximum | -tolerated dose (MTD) or the optimal biological dose (OBD | ) for noncytotoxic agents. However, the conventional 3

关键词： Phase I dose-finding studies | small sample size | model-based designs | model-assisted designs | 3+3 algorithm | CONTINUAL REASSESSMENT METHOD | I CLINICAL-TRIALS | EXPANSION COHORTS | ORDINAL TOXICITY | INTERVAL DESIGN...

摘要： efficacy of the RP2D in expansion cohorts of selected R/R | A significant unmet need remains for patients | with Hodgkin lymphoma (HL) who fail to respond to | first-line treatment or experience an early relapse | . Tinostamustine, a novel alkylating deacetylase inhibitor